We have recently pointed to the potentially beneficial effects of cholesterol-lowering therapy in preventing endothelial dysfunction and thrombotic events in HeFH patients with COVID-19, particularly when a statin is combined with a PCSK9 inhibitor (37). This evidence concerns the gene PCSK9 and COVID-19.